Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Melbourne, Australia, July 21, 2023 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’
or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid
pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to
announce that it has successfully submitted an Investigational New Drug (‘IND’) application to the US
Food and Drug Administration (‘FDA’) for IHL-42X for treatment of obstructive sleep apnoea.